NA
TSBX

Nordwand Advisors’s Turnstone Biologics TSBX Stock Holding History

Nordwand Advisors’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$8.2K – 210
2025
Q1 		$8.2K Buy
+20,000
New +$8.51K ﹤0.01% 83
2024
Q3 		– Sell
-1,500
Closed -$3.93K – 168
2024
Q2 		$3.93K Buy
+1,500
New +$4.29K ﹤0.01% 128

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nordwand Advisors's TSBX Position: Q2 2025 in Review

Nordwand Advisors sold out of Turnstone Biologics (TSBX) in Q2 2025, closing a stake of 20,000 shares — an estimated $8.2K sold.

Nordwand Advisors first reported a position in TSBX in Q2 2024 and held it in 2 quarters. The position peaked at $8.2K in Q1 2025. 23 funds tracked by Wall St. Rank hold TSBX as of Q2 2025.

  • Nordwand Advisors reported no remaining Turnstone Biologics position as of Q2 2025 after selling out during the quarter.
  • Nordwand Advisors sold 20,000 Turnstone Biologics shares in Q2 2025, an estimated $8.2K.
  • Nordwand Advisors first reported a position in Turnstone Biologics in Q2 2024 and held it in 2 quarters.
  • Nordwand Advisors's Turnstone Biologics position peaked at $8.2K in Q1 2025.
  • 23 funds tracked by Wall St. Rank held Turnstone Biologics as of Q2 2025.

Based on Nordwand Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.